🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSemaglutide (Ozempic / Wegovy)My compounded sema journey — anyone have experience?

My compounded sema journey — anyone have experience?

hans_munich Tue, Sep 2, 2025 at 2:49 PM 13 replies 1,415 viewsPage 1 of 3
This thread is more than 9 months old. Information may be outdated. Consider searching for more recent discussions.
hans_munich
Member
534
2,345
Jul 2024
Munich, DE
Sep 2, 2025 at 2:49 PM#1

Writing this once so I can stop repeating it across threads. It is about compounded supply, and it is deliberately narrow — everything I am not confident about is marked as such.

What is actually established

Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists. For 503B the shortage clause was the only route to these molecules, so that route shut completely. A 503A pharmacy can still argue a doorway via "component of an approved drug" — but only for the substance in the form present in the approved product, which is exactly where the base-versus-salt argument lives, and it does nothing about the copy restriction, which came back into force on resolution.

The condition it depends on

The enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured inventory and clinic contracts to unwind while a 503A makes to order.

The practical version

Two things anyone can check: a state licence number for a 503A, and an FDA outsourcing-facility registration for a 503B. Both are publicly searchable, and a pharmacy unwilling to give you either has answered the question.

What I am not sure about

The narrow version of the question is what actually distinguishes 503A from 503B, in terms of what each may make and from what starting material. Practical detail welcome, however dull — the duller the better.

— hans_munich · corrections welcome and will be edited into this post with credit
25 20kevin_tulsa, Dr.PainCLE, mike_mealprep and 22 others
Reply Quote Save Share Report
DanielChem_CHI
Senior Member
1,234
5,678
Mar 2024
Chicago, IL
Sep 2, 2025 at 3:01 PM#2
hans_munich said:
Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.

That is correct as far as it goes, and here is where it stops going. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

24 19Dr.DermMIA, fiona_VT, denise_HTX and 21 others
Reply Quote Save Share Report
kate.chem
VIP Member
3,890
17,654
Dec 2023
California
Sep 2, 2025 at 3:13 PM#3
hans_munich said:
Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.

Pushing back on hans_munich here. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.

23 18tyler_CSCS, VanRx_Mike, steve_okc and 20 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
sarah_TO
Member
278
1,234
Sep 2024
Toronto, CA
Sep 2, 2025 at 3:25 PM#4

Answering the narrow version, because the broad one does not have a single answer. They are two different exemptions from the same federal requirements and they buy different things. A 503A pharmacy is regulated primarily by the state board, needs a patient-specific prescription, is exempt from CGMP, and may use a bulk substance that has a USP monograph, is a component of an approved drug, or appears on the 503A bulks list — three independent doorways. A 503B outsourcing facility registers with the FDA, is inspected on a risk basis, must comply with CGMP, may compound for office stock without a patient-specific prescription, and has one doorway to a permitted bulk substance: the 503B bulks list, or the drug shortage list.

22 17carl_compliance, DanielChem_CHI, marco_milano and 19 others
Reply Quote Save Share Report
SallyK_inj
Member
567
2,345
Jul 2024
Iowa
Sep 2, 2025 at 4:29 PM#5
DanielChem_CHI said:
The shortage clause is the answer to the second question and it is a subtraction rather than an addition.

Adding a me-too, because a thread of one person's experience is not much use.

Last edited: Sep 2, 2025 at 5:29 PM
21 16Dr.PathRoch, mona_PHX, andrew_nyc and 18 others
Reply Quote Save Share Report

Similar Threads

STEP 1-5 trials comprehensive summary — efficacy endpoints compiled12 replies
Oral semaglutide 50mg Phase 3 — OASIS program results16 replies
Semaglutide pharmacokinetics — half-life, Tmax, steady state modeling10 replies
Compounded semaglutide stability data — temperature and light sensitivity16 replies
0.25mg → 2.4mg titration: optimal schedule based on clinical data6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register